| Not Yet Recruiting | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | 2026-06-01 |
| Not Yet Recruiting | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Multiple Sclerosis | Phase 2 | 2026-03-21 |
| Recruiting | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcu Relapsing Multiple Sclerosis | Phase 3 | 2025-07-09 |
| Recruiting | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune B-cell Mediated Autoimmune Disorders | Phase 1 | 2025-05-06 |
| Recruiting | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Rela Relapsing Multiple Sclerosis, Multiple Sclerosis | — | 2024-07-22 |
| Recruiting | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis | — | 2024-06-01 |
| Recruiting | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk Relapsing Multiple Sclerosis | — | 2024-03-26 |
| Recruiting | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab Relapsing Multiple Sclerosis | Phase 3 | 2023-06-13 |
| Terminated | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy CLL, SLL, Richter's Transformation | Phase 1 | 2021-04-28 |
| Active Not Recruiting | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis (RMS) | Phase 3 | 2019-11-18 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Chronic Lymphocytic Leukemia | Phase 2 | 2019-08-05 |
| Terminated | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | 2019-07-10 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 / Phase 3 | 2019-05-16 |
| Terminated | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma B-cell Non Hodgkin Lymphoma, Richter's Transformation | Phase 1 | 2019-04-17 |
| Completed | Study of TG-1801 in Subjects With B-Cell Lymphoma B-Cell Lymphoma | Phase 1 | 2019-03-05 |
| Terminated | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | 2018-09-10 |
| Terminated | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | 2018-03-27 |
| Completed | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma | Phase 2 | 2017-11-30 |
| Completed | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclero Relapsing Multiple Sclerosis (RMS) | Phase 3 | 2017-09-19 |
| Completed | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclero Relapsing Multiple Sclerosis (RMS) | Phase 3 | 2017-08-25 |
| Terminated | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 2 | 2017-08-09 |
| Completed | An Extension of the TG1101-RMS201 Trial Relapsing Remitting Multiple Sclerosis | Phase 2 | 2017-06-01 |
| Completed | Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis Multiple Sclerosis | Phase 2 | 2016-05-27 |
| Terminated | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisi Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 / Phase 3 | 2016-05-25 |
| Terminated | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intoler Chronic Lymphocytic Leukemia | Phase 2 | 2016-04-21 |
| Terminated | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Pre Chronic Lymphocytic Leukemia | Phase 2 | 2016-01-07 |
| Terminated | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously T Chronic Lymphocytic Leukemia | Phase 3 | 2015-11-19 |
| Completed | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 1 | 2015-09-18 |
| Completed | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Sel Pancreatic Cancer, Colorectal Cancer, Rectal Cancer | Phase 1 | 2015-09-11 |
| Completed | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High- Chronic Lymphocytic Leukemia | Phase 3 | 2015-01-27 |
| Completed | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients Hodgkin's Lymphoma | Phase 1 | 2014-06-11 |
| Completed | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic L Chronic Lymphocytic Leukemia | Phase 1 | 2014-03-12 |
| Completed | Ublituximab + Ibrutinib in Select B-cell Malignancies Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2014-01-06 |
| Completed | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | 2013-12-13 |
| Completed | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma | Phase 1 | 2013-01-07 |
| Terminated | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | 2012-11-21 |
| Completed | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lym Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia | Phase 1 / Phase 2 | 2012-07-19 |